These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3459398)

  • 1. [Early phase II trial of bestrabucil in hematological malignancies].
    Nagura E; Ohno R; Yamada K; Akao Y; Naito K; Nishikawa M; Tanaka H; Shirakawa S; Ono Y; Ezaki K
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2216-22. PubMed ID: 3459398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical trial of bestrabucil (KM 2210) on hematopoietic malignancies].
    Nishikawa M; Uemura Y; Matsuoka N; Ohno T; Katayama N; Tomeoku M; Kobayashi T; Kita K; Tanaka H; Minami N
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2155-9. PubMed ID: 3521494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical trial of bestrabucil (KM 2210) in hematopoietic malignancies].
    Naito K; Kubo K; Akao Y; Hiraiwa A; Naoe T; Yamada K
    Gan No Rinsho; 1986 Sep; 32(11):1443-50. PubMed ID: 2877106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase II study of chlorambucil in patients with hematological malignancies].
    Inoue K; Ogawa M; Horikoshi N; Mukaiyama T; Itoh Y; Imajoh K; Ozeki H; Nagamine D; Shinagawa K
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2672-5. PubMed ID: 3307632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase I study of bestrabucil (KM 2210)].
    Kamei H; Takenaka K; Goto T; Suga S; Fugiwara A; Nakao I; Agatsuma T; Fujita K; Isurugi K; Kubota T
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2208-15. PubMed ID: 3755019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase II study of prednimustine in follicular lymphoma and chronic lymphocytic leukemia].
    Ito Y; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ueno K; Imajou K; Miyaoka K; Ozeki H
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):173-8. PubMed ID: 3541792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
    Ueda T; Sakai K; Morimoto K; Nakatani S
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3285-9. PubMed ID: 3688892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect.
    Nishikawa M; Uemura Y; Komada F; Ohno T; Katayama N; Shirakawa S
    Jpn J Clin Oncol; 1988 Dec; 18(4):327-33. PubMed ID: 3204682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [KM 2210 therapy for chronic lymphocytic leukemia].
    Mori M; Murai Y; Miwa A; Fukayama M; Ikebuchi K; Nakamura N; Kaise M
    Gan No Rinsho; 1983 Dec; 29(15):1788-90. PubMed ID: 6689433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A phase II study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) in patients with hematological malignancies. THP Study Group].
    Kimura K
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):368-75. PubMed ID: 3947112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
    Tanaka I; Kobayashi T; Shirakawa S; Ikeda Y; Kobayashi M; Yamagata K; Ohta K; Ohno R; Yamada H; Yamada K
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):493-8. PubMed ID: 3859248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects of bestrabucil (KM2210) in bladder cancer].
    Nasu Y; Saegusa M; Ochi J; Hara M; Akagi T; Obama T; Yoshimoto J; Matsumura Y; Ohmori H; Tsushima T
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3155-6. PubMed ID: 3674900
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma.
    Arimori S; Nagao T; Shimizu Y; Watanabe K; Komatsuda M
    Tokai J Exp Clin Med; 1980 Jan; 5(1):63-71. PubMed ID: 6930119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bestrabacil: a possible target-oriented anticancer agent].
    Ohsawa N; Yamazaki Z; Wagatsuma T; Isurugi K
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2115-24. PubMed ID: 6548354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of vindesine in hematological malignancies].
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2509-15. PubMed ID: 6580841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Single-agent trial with epirubicin in hematological malignancies].
    Kobayashi T; Tanaka I; Ohta C; Katayama N; Ohno T; Uchida T; Shimizu N; Furuta I; Matsuoka N; Shima N
    Gan No Rinsho; 1987 Feb; 33(2):184-7. PubMed ID: 3470533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of Prednimustine (Leo 1031) in chronic lymphatic leukemia].
    Lutz D; Böhnel J
    Osterr Z Onkol; 1977; 3(5-6):155-9. PubMed ID: 323777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II study with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies].
    Higuchi A; Miyazaki T; Sakurada K; Morioka M; Musashi M; Imamura M; Maekawa I; Saitoh H; Ohtani N; Kasai M
    Gan To Kagaku Ryoho; 1985 Jun; 12(6):1253-9. PubMed ID: 3859250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. m-AMSA: phase II trial in advanced lymphoma and leukemia.
    Case DC
    Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C.
    Biomedicine; 1977 Jun; 27(4):158-61. PubMed ID: 329910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.